Charles River Laboratories International, Inc. (NYSE:CRL) Stock Holdings Reduced by Polen Capital Management LLC

Polen Capital Management LLC cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 22.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,248 shares of the medical research company’s stock after selling 1,256 shares during the period. Polen Capital Management LLC’s holdings in Charles River Laboratories International were worth $784,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP raised its holdings in Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after buying an additional 3,738,018 shares in the last quarter. State Street Corp raised its stake in shares of Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after acquiring an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock worth $330,231,000 after purchasing an additional 47,221 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Charles River Laboratories International by 7.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 552,975 shares of the medical research company’s stock worth $102,079,000 after purchasing an additional 37,753 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after purchasing an additional 85,759 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. This represents a 18.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Birgit Girshick acquired 1,514 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CRL. Bank of America reduced their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. JPMorgan Chase & Co. decreased their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Morgan Stanley cut their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. Finally, Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target on the stock in a research report on Monday, March 3rd. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Hold” and a consensus price target of $198.36.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $175.02 on Tuesday. The firm has a market capitalization of $8.95 billion, a PE ratio of 1,166.77, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $274.77. The firm has a 50-day moving average price of $167.46 and a 200 day moving average price of $184.33.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.46 EPS. Research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).